With the emergence of brain-penetrant Nlrp3 inhibitors, future investigations should focus on examining whether pharmacological targeting of the Nlrp3 inflammasome can effectively suppress the formation of neurofibrillary tangles in AD and other tauopathies. The gene discussed is NLRP3; the disease is tauopathy.